Stifel Reiterates Buy Rating on Iveric Bio (ISEE) as Zimura 'Checks All Efficacy AND Safety Boxes'

Iveric Bio (ISEE) PT Raised to $30 at Cowen; Zimura Has Solid Profile in Likely $4B+ Market

September 6, 2022 11:16 AM EDT

Cowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $30.00 (from $25.00) while maintaining a Outperform rating following Zimura results, saying it has a solid profile in likely $4B+ market.

The analyst commented, "Iveric bio disclosed positive results from Zimura's... More

B.Riley Downgrades Iveric Bio (ISEE) to Sell

September 6, 2022 11:06 AM EDT

B.Riley analyst Yuan Zhi downgraded Iveric Bio (NASDAQ: ISEE) from Neutral to Sell with a price target of $8.00 (from $12.00).

For an analyst ratings summary and ratings history on Iveric Bio click here. For more ratings news on Iveric Bio click here.

Shares of Iveric Bio closed at $9.44 yesterday.

... More

Iveric Bio (ISEE) PT Raised to $27 at Credit Suisse

September 6, 2022 10:33 AM EDT

Credit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $27.00 (from $24.00) while maintaining a Outperform rating.

The analyst comments "Competitive Dynamic Nuanced, but Valuation Gap Still Favors ISEE Shares. We expect the debate to now shift to... More

JPMorgan Positive on Apellis Pharmaceuticals (APLS): 'we believe that pegcetacoplan’s pole position in the disease space has been solidified'

September 6, 2022 10:25 AM EDT

JPMorgan analyst Anupam Rama reiterated an Overweight rating on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "On BCVA pushback related to pegcetacoplanEarly pushback this morning related to pegcetacoplan has focused on a favorable trend" for Zimura 2mg on BCVA in GATHER2... More

UPDATE: Wells Fargo Out on Apellis Pharmaceuticals (APLS), Says Equity Pricing in Too Much Risk

September 6, 2022 10:20 AM EDT

(Updated - September 6, 2022 10:29 AM EDT)

Wells Fargo analyst Chris M. Carey reiterated an Overweight rating and $84.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)

" ISEE's GATHER2 Data Are Positive Though We Think APLS' Pegcetacoplan Still Has the Edge"

The analyst comments "We are... More

Increasing unusual option volume: ISEE AVCT SGFY HEAR TECS CS ING HNST

September 6, 2022 9:51 AM EDT

Increasing unusual option volume: ISEE AVCT SGFY HEAR TECS CS ING HNST

... More

Apellis Pharmaceuticals (APLS) weakness appears related to data from IVERIC bio (ISEE) in geographic atrophy

September 6, 2022 8:24 AM EDT

Apellis Pharmaceuticals (NASDAQ: APLS) weakness appears related to data from IVERIC bio (NASDAQ: ISEE) in geographic atrophy

lSEE +28%APLS -4.3%... More

Guggenheim on Iveric Bio (ISEE) Gather 2: 'We Expect Approval'

September 6, 2022 7:32 AM EDT

Guggenheim analyst Eddie Hickman reiterated a Buy rating on Iveric Bio (NASDAQ: ISEE).

The analyst comments "This morning, ISEE announced that GATHER 2 met its primary endpoint showing a 14.3% reduction in mean rate of growth (slope) over 12 months (reduction was 17.7% was used using observed GA area. We note that while the drug... More

IVERIC bio (ISEE) Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy Met Primary Endpoint

September 6, 2022 6:54 AM EDT

IVERIC bio, Inc. (Nasdaq: ISEE) today announced positive topline results from GATHER2, the Companys second Phase 3 clinical trial of Zimura® (avacincaptad pegol), a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA). GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months... More